Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 7—July 2024
Research Letter

World Health Organization Enhanced Gonococcal Antimicrobial Surveillance Programme, Cambodia, 2023

Vichea Ouk, Heng Lon Say, Mot Virak, Serakea Deng, Rebekah Frankson, Robert McDonald, Ellen N. Kersh, Teodora Wi, Ismael Maatouk, Sebastiaan van Hal, Monica M. LahraComments to Author , and for the EGASP Cambodia working group1
Author affiliations: National Center for HIV/AIDS, Dermatology and Sexually Transmitted Diseases, Phnom Penh, Cambodia (V. Ouk, H.L. Say); Laboratory of the National Institute of Public Health, Phnom Penh (M. Virak); World Health Organization Office of Cambodia, Phnom Penh (S. Deng); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (R. Frankson, R. McDonald, E.N. Kersh); World Health Organization, Geneva, Switzerland (T. Wi, I. Maatouk); The University of Sydney, Sydney, New South Wales, Australia (S.J. van Hal); The Prince of Wales Hospital, Randwick, New South Wales, Australia (M.M. Lahra); The University of New South Wales, Sydney (M.M. Lahra)

Main Article

Table

Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from the World Health Organization EGASP, Cambodia, 2022–2023*

​Antimicrobial drug ​​2022, n = 76, no. (%) (2) ​2023, n = 72, no. (%)
​Ceftriaxone >0.125 μg/mL† ​29 (38) ​22 (31)
​Cefixime >0.25 μg/mL† ​29 (38) ​22 (31)
​Azithromycin >2.0 μg/mL† ​0 ​1 (1.4)
Azithromycin >256 μg/mL† ​3 (4) ​9 (12.5)
​Ciprofloxacin resistant >1 μg/mL‡ ​74 (97) ​70 (97)
​Penicillin resistant >2 μg/mL‡ 71 (93) 59 (82)
​Spectinomycin resistant >128 μg/mL‡ ​0 ​0

*EGASP, Enhanced Gonococcal Antimicrobial Surveillance Programme. †The Clinical Laboratory Standards Institute criteria for resistance to ceftriaxone, cefixime, and azithromycin have not been established. The EGASP MIC alert value criteria were ceftriaxone, MIC >0.125 μg/mL; cefixime, MIC >0.25 μg/mL; azithromycin, MIC >2.0 μg/mL; and azithromycin, MIC >256 μg/mL. ‡Antimicrobial susceptibility criteria established by the Clinical Laboratory Standards Institute (https://www.clsi.org) were used to determine resistance to the antibiotics tested in the EGASP for ciprofloxacin, penicillin, and spectinomycin.

Main Article

1Members are listed at the end of this article.

Page created: May 23, 2024
Page updated: June 22, 2024
Page reviewed: June 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external